TY - JOUR
T1 - CD46 regulates hepatitis B virus entry by modulating cell-surface NTCP levels through cis-interaction
AU - Miyakawa, Kei
AU - Nakai, Yusuke
AU - Kameya, Taichi
AU - Nishitsuji, Hironori
AU - Watashi, Koichi
AU - Takeda, Makoto
AU - Seya, Tsukasa
AU - Shimotohno, Kunitada
AU - Kimura, Yayoi
AU - Ryo, Akihide
N1 - Publisher Copyright:
© The Author(s) (2025). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, CEMCS, CAS. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact [email protected]
PY - 2026
Y1 - 2026
N2 - Hepatitis B virus (HBV) infection remains a major global health challenge. While sodium taurocholate co-transporting polypeptide (NTCP) is the primary receptor for HBV entry, the molecular mechanisms regulating NTCP-mediated viral entry remain incompletely understood. Here, we identified CD46 as a crucial regulatory factor for NTCP membrane expression. We found that CD46 interacted with NTCP in cis at the plasma membrane through proximity-based labeling screening. The depletion of CD46 significantly reduced cell-surface NTCP levels and HBV infection in hepatocytes. Anti-CD46 monoclonal antibodies, particularly clone E4.3, inhibited HBV infection by triggering NTCP internalization from the plasma membrane to intracellular vesicles. The antiviral effect of CD46 antibodies was also confirmed in primary human hepatocytes. Our study reveals a previously unknown mechanism regulating NTCP-mediated HBV entry and suggests CD46 as a potential therapeutic target for HBV infection.
AB - Hepatitis B virus (HBV) infection remains a major global health challenge. While sodium taurocholate co-transporting polypeptide (NTCP) is the primary receptor for HBV entry, the molecular mechanisms regulating NTCP-mediated viral entry remain incompletely understood. Here, we identified CD46 as a crucial regulatory factor for NTCP membrane expression. We found that CD46 interacted with NTCP in cis at the plasma membrane through proximity-based labeling screening. The depletion of CD46 significantly reduced cell-surface NTCP levels and HBV infection in hepatocytes. Anti-CD46 monoclonal antibodies, particularly clone E4.3, inhibited HBV infection by triggering NTCP internalization from the plasma membrane to intracellular vesicles. The antiviral effect of CD46 antibodies was also confirmed in primary human hepatocytes. Our study reveals a previously unknown mechanism regulating NTCP-mediated HBV entry and suggests CD46 as a potential therapeutic target for HBV infection.
KW - hepatitis B virus (HBV)
KW - proximity-based labeling
KW - sodium taurocholate co-transporting polypeptide (NTCP)
KW - viral entry
UR - https://www.scopus.com/pages/publications/105046042483
UR - https://www.scopus.com/pages/publications/105046042483#tab=citedBy
U2 - 10.1093/jmcb/mjaf055
DO - 10.1093/jmcb/mjaf055
M3 - Article
C2 - 41432296
AN - SCOPUS:105046042483
SN - 1674-2788
VL - 18
JO - Journal of Molecular Cell Biology
JF - Journal of Molecular Cell Biology
M1 - mjaf055
ER -